These findings emphasize the need for a therapy to overcome treatment induced lymphopenia with higher mortality as presented at ASCO 2025 by several institutions (Abstract #8054, Satoskar et al.

Dr. Hui Zhou, Senior Vice President of Innovent, stated: "On top of the preliminary data reported at 2024 ASCO and 2024 ESMO, we are presenting more updated follow-up data and combination therapy ...

“Because of this complexity, we wanted to introduce Protocol Optimization at ASCO to give researchers a deeper look into how balancing scientific intention and practical execution can bring ...

ASCO ends tomorrow, but alas, dear readers, this newsletter’s run of show is over. At least until next year.

ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in ...

As Ascentage Pharma returns to the ASCO Annual Meeting for the eighth consecutive year, two studies of lisaftoclax and MDM2-p53 inhibitor alrizomadlin (APG-115), key drug candidates in the company ...

Credit: Inna Dodor/Shutterstock. Harbinger Health has reported clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, US, highlighting the performance ...

Patients with tenosynovial giant cell tumor can take some comfort in knowing that this rare type of tumor affecting joints won’t kill them. But that doesn’t make living with the disease easy.

The Securities and Exchange Board of India (SEBI) has confirmed the suspension of LS Industries, its promoter Profound Finance, and four other individuals from participating in the securities markets.

The Journal of Clinical Oncology podcast, hosted by Dr. Shannon Westin and Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of ...

Perspective Therapeutics, Inc. presented updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting, showing a favorable safety profile ...